Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer

被引：2

作者：

Salomaa, ER ^{[1
]}

Liippo, K ^{[1
]}

Ellmen, J ^{[1
]}

Komi, J ^{[1
]}

机构：

[1] ORION CORP FARMOS,FIN-20101 TURKU,FINLAND

来源：

LUNG CANCER | 1996年 / 16卷 / 01期

关键词：

non-small cell lung cancer; chemotherapy; multi-drug resistance; toremifene; ifosfamide;

D O I：

10.1016/S0169-5002(96)00613-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The efficacy and safety of toremifene-ifosfamide as a first-line chemotherapy in non-small cell lung cancer were assessed. Sixteen patients were treated with oral toremifene (420 mg on days 1-4 and 240 mg on day 5) followed by ifosfamide infusion 5 g/m(2) on day 5 every 3 weeks 1-6 times. Toremifene at the doses used did not enhance the effect or toxicity of ifosfamide in previously untreated non-small cell lung cancer patients. Copyright (C) 1996 Elsevier Science Ireland Ltd.

引用

页码：75 / 80

页数：6

共 10 条

[1]

Agresti A., 1990, CATEGORIAL DATA ANAL

[2]

BAKER WJ, 1992, P AM SOC CLIN ONCOL, V11, P109

[3] TOREMIFENE - PHARMACOLOGIC AND PHARMACOKINETIC BASIS OF REVERSING MULTIDRUG RESISTANCE [J].

DEGREGORIO, MW ;

FORD, JM ;

BENZ, CC ;

WIEBE, VJ .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (09) :1359-1364

[4]

ETTINGER DS, 1989, SEMIN ONCOL S3, V16, P3

[5]

KANGAS L, 1982, 11 OR CORP

[6] CHEMOSENSITIZING EFFECT OF AN ANTIESTROGEN, TOREMIFENE, ON OVARIAN-CANCER [J].

MAENPAA, J ;

SIPILA, P ;

KANGAS, L ;

KARNANI, P ;

GRONROOS, M .

GYNECOLOGIC ONCOLOGY, 1992, 46 (03) :292-297

[7]

OZOLS RF, 1988, P AM ASSOC CANC RES, V29, P526

[8]

SHIN HJC, 1992, ANTICANCER RES, V12, P367

[9]

VIRTANEN R, 1986, 3 OR CORP

[10]

WURZ GT, 1992, CANC CHEMOTHER PHARM, V31, P412

← 1 →